Protocol Ledger

NCT06880523 · Phase II · RECRUITING

STRIDE (Durvalumab + Tremelimumab) With Lenvatinib vs STRIDE Alone in Unresectable Hepatocellular Carcinoma

Interventional Phase II clinical trial protocol NCT06880523 sponsored by Canadian Cancer Trials Group in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-10-21 Enrollment: 140 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06880523
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)140 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06880523
Protocol FieldVerified Registry Value
NCT IdentifierNCT06880523
Consolidated Lead SponsorCanadian Cancer Trials Group
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusRECRUITING
Registered Enrollment140 participants (ESTIMATED)
Registered Start Date2025-10-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06880523
Hospital Research SiteLocationSite Profile
Arthur J E Child Comprehensive Cancer CentreCalgary, CanadaOpen Hospital Dossier ->

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI